



AGENIX LIMITED

爱健克斯有限公司

(ASX: AGX)

ABN 58 009 213 754

PO Box 5160

Burnley VIC 3121

Australia

www.agenix.com

30 August 2016

Company Announcements Office
Australian Stock Exchange
Level 6
20 Bridge Street
Sydney NSW 2000

Dear Sir/Madam

**AGENIX LIMITED (AGX)
ANNUAL RESULT FOR THE YEAR ENDED 30 JUNE 2016**

Attached is the financial information required by ASX Listing Rule 4.3A together with the company's Group preliminary financial statements for the year ended 30 June 2016.

Attached:

1. Appendix 4E detailing the preliminary announcement for the year ended 30 June 2016;
2. Preliminary financial statements and notes for the year ended 30 June 2016 are currently being audited.

Yours Faithfully

Gary Taylor

Gary Taylor
Chief Financial Officer/ Company Secretary
Agenix Limited
e: gtaylor@agenix.com

APPENDIX 4E



Agenix Limited
ABN 58 009 213 754

Results for announcement to the market

Reporting period: 12 months to 30 June 2016

Previous reporting period: 12 months to 30 June 2015

	Amount \$ 000's	Percentage change
Revenues from ordinary activities	30	Up 297%
Loss from ordinary activities after tax attributed to security holder	(271)	Down 65%
Loss from discontinued operations after tax attributed to security holder	(105)	Down 66%
Loss after tax attributed to security holder	(376)	Down 65%

Dividend Information

No dividend has been paid or declared in respect of the year ended 30 June 2016 or 30 June 2015.

Commentary on results for the period

The Group's loss for the year ended 30 June 2016 was \$376,510 compared to a loss of \$1,083,446 in the previous financial year. The loss is primarily attributed to:

- one off costs associated with the repatriation of funds from China and the voluntary liquidation of the Chinese subsidiary which was completed in March 2016 totalling \$78,858;
- costs incurred in respect of the review of potential acquisitions and due diligence undertaken totalling \$72,741; and
- a charge to the statement of profit and loss and other comprehensive income amounting to \$11,905, being the non-cash fair value of the securities issued to OKS AGX Inc. in accordance with accounting standards.

Total income for the year ended 30 June 2016 was \$30,423 up from \$7,657 in the previous financial year due to interest being earned on funds invested.

Operating expenses (excluding OKS charge) for the year totalled \$259,469 compared with the previous financial year of \$581,684 the Group continued to reduce costs and cash burn wherever possible whilst it reviewed strategic alternatives.

Current assets at 30 June 2016 were \$321,917 (2015: \$1,694,819). Total liabilities at 30 June 2016 were \$133,426 (2015: \$846,100). Current assets reduced due to the use of cash to settle all outstanding liabilities in respect of loans advanced by the Directors and their related parties pending receipt of funds from China. The decrease in current liabilities is mainly due to the loans

APPENDIX 4E

being advanced by directors to enable the Company to meet its obligations whilst the process of repatriation of funds from China was completed being repaid in December 2015. The interest bearing loan shown as current and noncurrent assets represents the amount advanced to CCP Holdings Pty Ltd pending the completion of the acquisition.

Financial Information

This Appendix 4E should be read in conjunction with the preliminary consolidated financial statements for the year ended 30 June 2016 as attached.

Net tangible assets

	2016	2015
Net tangible assets per ordinary security (cents)	0.003	0.005

Details of Entities over which control has been gained or lost

In December 2015, the Company obtained all necessary regulatory approvals in China to repatriate the funds held there. Following the repatriation of funds, the voluntary liquidation of the Chinese subsidiary, Agenix Biopharmaceutical (Shanghai) Co. Limited was completed in March 2016.

Australian Accounting Standards

The financial information provided in this Appendix 4E is based upon the Annual Financial Report, which has been prepared in accordance with Australian Accounting Standards and is currently being audited by BDO Audit Pty Ltd.

Commentary on Results for the year

Refer above.

Additional Information

On 24 March 2016 the Company entered into a Share Sale Agreement with CCP Group to acquire all its interests. An Extraordinary General Meeting of Shareholders was held on 29 June 2016 to approve the acquisition and associated resolutions. The resolutions were passed unanimously. A Prospectus was lodged with ASIC on 30 June 2016 which sought to raise \$3 Million to fund the ongoing business of CCP and payment of costs associated with the Prospectus. As a result, the Company has been suspended from the Official List pending readmission pursuant to Chapters 1 and 2 of the ASX Listing Rules.

The Prospectus was closed oversubscribed on 24 August 2016. The oversubscription results in the Directors entitlement to participate (as approved by shareholders) in the Offer to be reduced to ensure that the maximum amount of \$3,000,000 as set out in the prospectus is adhered to.

The application for readmission to the Official List is currently with the ASX for consideration.

APPENDIX 4E

Whilst the company is not aware of any circumstances which would result in the ASX not approving the readmission, the final decision is made by the ASX.

-end-



AGENIX LIMITED

ABN 58 009 213 754

APPENDIX 4E

PRELIMINARY FINANCIAL REPORT

FOR THE YEAR ENDED

30 JUNE 2016

AGENIX LIMITED
PRELIMINARY FINANCIAL REPORT
FOR THE YEAR ENDED 30 JUNE 2016

STATEMENT OF PROFIT AND LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE YEAR ENDED 30 JUNE 2016

	Consolidated	
	2016 \$	2015 \$
Revenue	30,423	7,657
Depreciation and amortisation expense	-	(516)
Employee benefit expense	(222,791)	(291,960)
Finance costs	(27,544)	(34,739)
Foreign exchange gains (losses)	7,196	46,056
Occupancy and administrative expenses	(221,454)	(301,743)
Foreign exchange gain on capital repatriation - China	174,701	-
Fair value of OKS settlement	(11,905)	(198,600)
Loss before income tax expense from continuing operations	(271,374)	(773,845)
Income tax expense	-	-
Loss for the year after tax from continuing operations	(271,374)	(773,845)
Loss after income tax from discontinued operations	(105,136)	(309,601)
Loss after income tax expense for the year	(376,510)	(1,083,446)
Other comprehensive income		
Items that may be reclassified to profit or loss		
Exchange differences on translating foreign controlled entities	(177,282)	280,124
Other comprehensive income for the year, net of tax	-	280,124
Total comprehensive income for the year	(177,282)	(803,322)
Loss attributed to owners of Agenix Limited	(376,510)	(1,083,446)
Total Comprehensive Income attributed to owners of Agenix Limited	(553,792)	(803,322)
Earnings per share for loss from continuing operations attributable to the owners of Agenix Limited		
Basic earnings	(\$0.0003)	(\$0.0057)
Diluted earnings	(\$0.0003)	(\$0.0057)
Earnings per share for profit/ (loss) from discontinued operations attributable to the owners of Agenix Limited		
Basic earnings	(\$0.0001)	(\$0.0023)
Diluted earnings	(\$0.0001)	(\$0.0023)
Earnings per share for profit/(loss) from attributable to the owners of Agenix Limited		
Basic earnings	(\$0.0004)	(\$0.0080)
Diluted earnings	(\$0.0004)	(\$0.0080)

The accompanying notes should be read in conjunction with these financial statements.

AGENIX LIMITED
PRELIMINARY FINANCIAL REPORT
FOR THE YEAR ENDED 30 JUNE 2016

AGENIX LIMITED
STATEMENT OF FINANCIAL POSITION
AS AT 30 JUNE 2016

	Note	Consolidated	
		2016 \$	2015 \$
ASSETS			
CURRENT ASSETS			
Cash and cash equivalents	1	33,416	1,668,559
Trade and other receivables		9,514	15,003
Prepayments		28,987	-
Interest bearing loan		250,000	-
		321,917	1,683,562
Assets of discontinued operations classified as held for sale	2	-	11,257
TOTAL CURRENT ASSETS		321,917	1,694,819
NON-CURRENT ASSETS			
Interest bearing loan		250,000	-
TOTAL NON-CURRENT ASSETS		250,000	-
TOTAL ASSETS		571,917	1,694,819
CURRENT LIABILITIES			
Trade and other payables		113,596	161,158
Financial liabilities		-	680,300
		113,596	841,458
Liabilities directly associated with assets classified as held for sale	2	19,830	4,642
TOTAL CURRENT LIABILITIES		133,426	846,100
TOTAL LIABILITIES		133,426	846,100
NET ASSETS		438,491	848,719
EQUITY			
Issued capital	3	77,594,403	77,454,998
Share based payment reserve		4,663,998	4,663,998
Foreign currency translation reserve		-	177,282
Accumulated losses		(81,819,910)	(81,447,559)
TOTAL EQUITY		438,491	848,719

AGENIX LIMITED
PRELIMINARY FINANCIAL REPORT
FOR THE YEAR ENDED 30 JUNE 2016

STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 JUNE 2016

Consolidated

	Issued Capital	Accumulated losses	Share based payment reserve	FX translation reserve	Total equity
	\$	\$	\$	\$	\$
Balance at 1 July 2014	77,190,398	(80,364,113)	4,663,636	(102,842)	1,387,079
Total comprehensive income for the year:					
Profit for the year	-	(1,083,446)	-	-	(1,083,446)
Other comprehensive income:					
Foreign currency translation reserve differences	-	-	-	280,124	280,124
Total comprehensive income for the year	-	(1,083,446)	-	280,124	(803,322)
Transactions with owners in their capacity as owners:					
Securities issued during the year, net of transaction costs	66,000	-	-	-	66,000
Fair value of securities issued - OKS	198,600				198,600
Share based payments	-	-	362	-	362
	264,600	-	362	-	264,962
Balance at 30 June 2015	77,454,998	(81,447,559)	4,663,998	177,282	848,719

The accompanying notes should be read in conjunction with these financial statements

AGENIX LIMITED
PRELIMINARY FINANCIAL REPORT
FOR THE YEAR ENDED 30 JUNE 2016

STATEMENT OF CHANGES I446N EQUITY
FOR THE YEAR ENDED 30 JUNE 2016

	Issued Capital	Accumulated losses	Share based payment reserve	FX translation reserve	Total equity
	\$	\$	\$	\$	\$
Balance at 1 July 2015	77,454,998	(81,447,559)	4,663,998	177,282	848,719
Total comprehensive income for the year:					
Loss for the year	-	(376,510)	-	-	(376,510)
Other comprehensive income:					
Foreign currency translation reserve differences	-	-	-	(177,282)	(177,282)
Total comprehensive income for the year	-	(376,510)	-	(177,282)	(553,792)
Transactions with owners in their capacity as owners:					
Securities issued during the year, net of transaction costs	127,500	-	-	-	127,500
Fair value of securities issued - OKS	11,905	-	-	-	11,905
	139,405	-	-	-	139,405
Changes in ownership interests					
Liquidation of China subsidiary	-	4,159	-	-	4,159
Balance at 30 June 2016	77,594,403	(81,819,910)	4,663,998	-	438,491

The accompanying notes should be read in conjunction with these financial statements

AGENIX LIMITED
PRELIMINARY FINANCIAL REPORT
FOR THE YEAR ENDED 30 JUNE 2016

STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 30 JUNE 2016

	Note	Consolidated	
		2016 \$	2015 \$
CASH FLOWS FROM OPERATING ACTIVITIES			
Receipts from customers		10,443	2,016
Payments to suppliers and employees		(557,845)	(817,897)
Payments relating to research and development		-	(78,066)
Interest received - bank		18,864	5,633
Finance costs		(27,818)	(36,749)
Net cash provided by (used in) operating activities		(556,356)	(925,063)
CASH FLOWS FROM INVESTING ACTIVITIES			
Payment for convertible note		(500,000)	
Proceeds from sale of intangible assets		-	2,079,124
Payments for costs on sale of intangible assets		-	(238,501)
Net cash provided by (used in) investing activities		(500,000)	1,840,623
CASH FLOWS FROM FINANCING ACTIVITIES			
Proceeds from borrowings		90,500	470,582
Repayment of borrowings		(690,500)	(95,582)
Net cash provided by (used in) financing activities		(600,000)	375,000
Net increase (decrease) in cash held		(1,656,356)	1,290,560
Cash at beginning of financial year		1,668,559	27,944
Effect of exchange rate of cash held in foreign currencies		21,213	350,055
Cash at end of financial year	1	33,416	1,668,559

The accompanying notes should be read in conjunction with these financial statements

AGENIX LIMITED
PRELIMINARY FINANCIAL REPORT
FOR THE YEAR ENDED 30 JUNE 2016

NOTES TO THE PRELIMINARY FINANCIAL REPORT

Note 1: Cash and cash equivalents

	Consolidated	
	2016	2015
	\$	\$
Cash at bank and in hand	33,416	1,668,559
Deposits on demand	-	-
Cash and cash equivalents	33,416	1,668,559

Cash at bank and in hand is non-interest bearing. Deposits on demand bear floating interest rate of 0.35% (2014: 1.4% and 3.5%). These deposits have an average maturity of 30 days, but are callable upon demand.

Reconciliation of cash

Cash at the end of the financial year as shown in the cash flow statement is reconciled to items in the Statement of Financial Position as follows:

Cash and cash equivalents	33,416	1,668,559
---------------------------	--------	-----------

Reconciliation of the net profit (loss) after tax to the net cash flows from operations

Net profit (loss) after income tax	(376,510)	(1,083,446)
------------------------------------	-----------	-------------

Non-cash items

Depreciation of non-current assets	-	516
Reversal of impairment AGX - 1009	-	-
Share based payment expense	-	362
Fair value of OKS Settlement	11,905	198,600
Equity settled expenditure	17,500	66,000
Equity settled – Directors fees	110,000	-
Unrealised net foreign currency (gains) losses	(8,378)	(41,539)
Foreign exchange gain on repatriation of funds	(174,701)	-
Other	-	(28,292)

Changes in assets and liabilities

Decrease (increase) in receivables	5,489	(8,251)
Decrease (increase) in prepayments and other current assets	(28,987)	3,664
(Decrease) increase in payables	(112,674)	(32,677)
Net cash provided by (used in) operating activities	(556,356)	(925,063)

AGENIX LIMITED
PRELIMINARY FINANCIAL REPORT
FOR THE YEAR ENDED 30 JUNE 2016

Note 2: Discontinued operations

In December 2015 all proceeds held in China were repatriated. The voluntary member's liquidation of the company's wholly owned subsidiary Agenix Biopharmaceutical (Shanghai) Company Limited was completed in March 2016.

Efforts to dispose of Thromboview are ongoing and as a result, the Board has determined that the intellectual property be offered for sale and therefore in accordance with accounting standards this major business line is continued to be treated as discontinued operations.

Financial performance information

	Consolidated					
	China	Thromboview	Total	China	Thromboview	Total
	2016	2016	2016	2015	2015	2015
	\$	\$	\$	\$	\$	\$
Interest received	-	-	-	-	-	-
Total revenue	-	-	-	-	-	-
Unrealised foreign exchange losses	-	-	-	(22,506)	-	(22,506)
Realised foreign exchange losses	-	(72)	(72)	-	(3,220)	(3,220)
Depreciation and amortisation	-	-	-	(2,514)	-	(2,514)
Research and development	-	(24,872)	(24,872)	-	(18,043)	(18,043)
Employee benefit expense	(1,315)	-	(1,315)	(111,517)	-	(111,517)
Corporate expenses	(77,543)	(1,334)	(78,877)	(89,925)	(4,991)	(94,916)
AGX-1009 assignment costs	-	-	-	(56,885)	-	(56,885)
Total expenses	(78,858)	(26,278)	(105,136)	(283,347)	(26,254)	(309,601)
Profit (Loss) before income tax expense	(78,858)	(26,278)	(105,136)	(283,347)	(26,254)	(309,601)
Income tax expense	-	-	-	-	-	-
Profit (Loss) after income tax expense	(78,858)	(26,278)	(105,136)	(283,347)	(26,254)	(309,601)

AGENIX LIMITED
PRELIMINARY FINANCIAL REPORT
FOR THE YEAR ENDED 30 JUNE 2016

Note 2: Discontinued operations (continued)
Financial performance information (continued)

	Consolidated					
	China	Thromboview	Total	China	Thromboview	Total
	2016	2016	2016	2015	2015	2015
	\$	\$	\$	\$	\$	\$
Profit on disposal before income tax	-	-	-	-	-	-
Income tax expense	-	-	-	-	-	-
Profit on disposal after income tax	-	-	-	-	-	-
Profit (Loss) after income tax expense on discontinued operations	(78,858)	(26,278)	(105,136)	(283,347)	(26,254)	(309,601)
Cash flow Information						
Net cash used in operating activities	(76,023)	(17,884)	(93,907)	(392,887)	(38,360)	(431,247)
Carrying amounts of assets and liabilities disposed						
Trade and other receivables	-	-	-	3,464	-	3,464
Prepayments	-	-	-	2,389	-	2,389
Plant and equipment	-	-	-	5,404	-	5,404
Total assets	-	-	-	11,257	-	11,257
Trade and other payables	-	19,830	19,830	-	4,642	4,642
Provisions	-	-	-	-	-	-
Total liabilities	-	19,830	19,830	-	4,642	4,642
Net assets	-	(19,830)	(19,830)	11,257	(4,642)	6,615

**AGENIX LIMITED
PRELIMINARY FINANCIAL REPORT
FOR THE YEAR ENDED 30 JUNE 2016**

Note 3: Capital and reserves

Share capital	Consolidated	
	2016	2015
	\$	\$
157,275,803 (2015: 149,030,675) ordinary securities	77,594,403	82,873,961
Less: 1,354,741 escrowed securities to SHRG vendors	-	(5,418,963)
157,275,803 (2015: 147,675,934) fully paid ordinary securities	77,594,403	77,454,998

Ordinary shares participate in dividends and the proceeds on winding up of the parent entity in proportion to the number of shares held. At the security holders' meetings each ordinary share is entitled to one vote when a poll is called, otherwise each Security holder has one vote on a show of hands.

The escrowed securities issued to SHRG vendors were cancelled during the year.

The following ordinary securities have been allotted during the year:

	Note	Consolidated			
		2016	2015	2016	2015
		\$	\$	No.	No.
Ordinary securities					
At the beginning of reporting period		77,454,998	77,190,398	149,030,675	130,947,876
Cancellation of SHRG vendor shares		-	-	(1,354,741)	-
Issue of securities for services rendered		17,500	20,000	1,206,899	1,670,386
Issue of securities in lieu of directors fees		110,000	46,000	7,571,970	3,172,413
Issue of securities in settlement of OKS AGX Inc. dispute	(a)	11,905	198,600	821,000	13,240,000
Balance as at 30 June		77,594,403	77,454,998	157,275,803	149,030,675

(a) In May 2015 shareholder approval was granted to issue 13,240,000 ordinary securities to OKS AGX Inc. This approval formed part of the settlement deed entered into by the Company with OKS AGX Inc. in full settlement of all claims arising from the 2007 placement arranged by the previous board and management. In accordance with the settlement deed the Company was required to maintain OKS AGX Inc. percentage shareholding for a period of 2 years or until such time as the Company entered into a significant transaction. No cash proceeds were received in consideration of these securities.

AGENIX LIMITED
PRELIMINARY FINANCIAL REPORT
FOR THE YEAR ENDED 30 JUNE 2016

Note 3: Capital and reserves (continued)

In accordance with AASB 2 Share based payment a fair value was required to be assigned to this transaction. Where a fair value cannot estimate reliably the fair value of the goods or services received, the company was required to measure their value, and the corresponding increase in equity, indirectly, by reference to the fair value of the equity instruments granted.

Options

Listed Options

No listed options were granted, issued or exercised nor have expired during the year ended 30 June 2016.

Unlisted Options

No unlisted options were granted, issued or exercised nor have expired during the year ended 30 June 2016.